The Adolescent and Young Adult with Cancer: State of the Art-- Acute Leukemias
- 754 Downloads
Despite survival gains over the past several decades, adolescent and young adult (AYA) patients with both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) demonstrate a consistent survival disadvantage. The AYA population exhibits unique disease and host characteristics, and further study is needed to improve their outcomes. This review will highlight distinctive aspects of disease biology in this population, as well as salient treatment-related toxicities including osteonecrosis, pancreatitis, thromboembolism, hyperglycemia, and infections. The impact of obesity and differences in drug metabolism and chemotherapy resistance will also be discussed, as well as optimal treatment considerations for the AYA population.
KeywordsAcute lymphoblastic leukemia Acute myeloid leukemia Adolescent Young adult Treatment-related toxicity Osteonecrosis Pancreatitis Thromboembolism Hyperglycemia Obesity Adherence
This work was supported by a Baylor College of Medicine Chao Physician-Scientist Award and a National Cancer Institute grant 1K23CA158148-01A1 to MMG; and by the Kurt Groten Family Research Scholars’ Program, the Gillson Longenbaugh Foundation, and a St. Baldrick’s Scholar Award to KRR.
Compliance with Ethics Guidelines
Conflict of Interest
M. Monica Gramatges declares no potential conflict of interest.
Karen R. Rabin declares no potential conflict of interest.
Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2004:118-45. doi: 10.1182/asheducation-2004.1.118.
- 9.Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187–205. doi: 10.1182/blood-2012-03-362608.PubMedCrossRefGoogle Scholar
- 11.Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372–9. doi: 10.1182/blood-2009-09-241075.PubMedCrossRefGoogle Scholar
- 13.Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101(10):3809–17. doi: 10.1182/blood-2002-08-2454.PubMedCrossRefGoogle Scholar
- 14.Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734–45. doi: 10.1111/j.1365-2141.2005.05509.x.PubMedCrossRefGoogle Scholar
- 15.Schrappe M, Zimmerman M, Moricke A, Mann G, Valsecchi M, Bartram C. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (Trial AIEOP-BFM ALL 2000). Blood. 2008;112:7.CrossRefGoogle Scholar
- 20.Mattano L, Nachman J, Devidas M, Winick N, Raetz E, Carroll W. Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children’s Oncology Group (COG). Blood. 2008;112:898.Google Scholar
- 21.Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-0. J Clin Oncol. 2013;31(9):1202–10. doi: 10.1200/JCO.2012.43.2070.
- 23.•• Nachman JB, La MK, Hunger SP, Heerema NA, Gaynon PS, Hastings C, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol. 2009;27(31):5189–94. doi: 10.1200/JCO.2008.20.8959. Results of a randomized phase III trial of 262 young adults with ALL demonstrate the benefit of early post-induction intensification therapy. The authors argue that the excellent outcomes on this trial support the use of chemotherapy rather than allogeneic stem cell transplant as front-line therapy for young adults with ALL.
- 31.French D, Hamilton LH, Mattano Jr LA, Sather HN, Devidas M, Nachman JB, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111(9):4496–9. doi: 10.1182/blood-2007-11-123885.PubMedCrossRefGoogle Scholar
- 32.Mattano Jr LA, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906–15. doi: 10.1016/S1470-2045(12)70274-7.PubMedCrossRefGoogle Scholar
- 33.Leblicq C, Laverdiere C, Decarie JC, Delisle JF, Isler MH, Moghrabi A, et al. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia. Pediatric blood & cancer. 2013;60(5):741–7. doi: 10.1002/pbc.24313.CrossRefGoogle Scholar
- 34.Winick N, Salzer W, Devidas M. Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children’s Oncology Group study AALL0232. Programs/Proceedings American Society of Clinical Oncology. 2011Google Scholar
- 38.Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol. 2005;129(6):803–10. doi: 10.1111/j.1365-2141.2005.05528.x.PubMedCrossRefGoogle Scholar
- 43.• Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25(15):2063–9. doi: 10.1200/JCO.2006.07.7792. Retrospective analysis of children with newly diagnosed ALL demonstrates an increased risk of relapse associated with obesity, with greatest risk in patients over 10 years of age.
- 52.• Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol. 2010;28(32):4790–9. doi: 10.1200/JCO.2010.28.3473. Comprehensive review of developmental physiology and behavioral characteristics that affect pharmacology of anti-cancer agents in the AYA population.
- 54.Maung ZT, Reid MM, Matheson E, Taylor PR, Proctor SJ, Hall AG. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia. Br J Haematol. 1995;91(1):93–100.PubMedCrossRefGoogle Scholar
- 56.Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007;25(7):813–9. doi: 10.1200/JCO.2006.08.6397.Google Scholar
- 57.Ribera JM, Oriol A, Sanz MA, Tormo M, Fernandez-Abellan P, del Potro E, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008;26(11):1843–9. doi: 10.1200/JCO.2007.13.7265.
- 60.Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol. 1999;106(2):436–44.PubMedCrossRefGoogle Scholar
- 61.Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19(10):2705–13.PubMedGoogle Scholar
- 62.•• Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106(11):2495–502. doi: 10.1002/cncr.21892. Retrospective review of 424 children with AML treated during two treatment eras (1983-1989 and 1990-2002) demonstrates an increased risk of adverse events associated with older age in the recent era, and an increased risk of death associated with increasing age in both treatment eras.PubMedCrossRefGoogle Scholar
- 63.Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22(21):4384–93. doi: 10.1200/JCO.2004.01.191.Google Scholar
- 66.Gramatges MM, Winter SS. Recommendations for broader coverage antifungal prophylaxis in childhood acute myeloid leukemia: ASH evidence-based review 2011. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2011;2011:374-6. doi:10.1182/asheducation-2011.1.374Google Scholar
- 67.Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93. doi: 10.1093/cid/cir073.PubMedCrossRefGoogle Scholar
- 70.Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2012;30(17):2094–101. doi: 10.1200/JCO.2011.38.9924.Google Scholar
- 71.• Butow P, Palmer S, Pai A, Goodenough B, Luckett T, King M. Review of adherence-related issues in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4800–9. doi: 10.1200/JCO.2009.22.2802. Review of issues and clinical challenges of nonadherence in AYA patients with cancer. While evidence-based research is lacking, this review provides a valuable outline of strategies for assessment and management of nonadherence, and areas where future research is needed.